Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BARD1 Y180fs BARD1 loss |
| Therapy | Irinotecan + Talazoparib |
| Indication/Tumor Type | neuroblastoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BARD1 Y180fs BARD1 loss | neuroblastoma | predicted - sensitive | Irinotecan + Talazoparib | Case Reports/Case Series | Actionable | In a clinical case study, treatment with the combination of Talzenna (talazoparib) and Camptosar (irinotecan) resulted in a complete response in a pediatric patient with high-risk relapsed/refractory neuroblastoma harboring germline BARD1 Y180fs and somatic Bard1 loss (PMID: 39141861). | 39141861 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39141861) | Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma. | Full reference... |